CHICAGO — The cancer drug Enhertu cut the rate of death in a group of women with advanced breast cancer by a third in a new clinical trial, a result that oncologists said could shift the way they think about treating the disease.
The makers of the medicine, Daiichi Sankyo and AstraZeneca, said that, if regulators clear the way, the number of patients eligible to receive the drug could be tripled, meaning that thousands of women in the U.S. alone could be offered a new life-extending option.
Click this link for the original source of this article.
Author: Matthew Herper
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.